EKF’s strong H1 results reflect the operational improvements implemented over the last 18 months. Recovery is now firmly established, with revenues +23% and EBITDA more than doubling in the period. After upgrading 6 times in the last 15 months, we prudently make no further changes at this stage. Growth prospects remain attractive, supported by additional product launches in new territories. We see further mileage as the group remains materially undervalued vs its closest peers and the investment ....
11 Sep 2017
N+1 Singer - EKF Diagnostics - Recovery phase complete, focusing on future
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - EKF Diagnostics - Recovery phase complete, focusing on future
EKF Diagnostics Holdings plc (EKF:LON) | 28.0 0 0.0% | Mkt Cap: 127.0m
- Published:
11 Sep 2017 -
Author:
Chris Glasper -
Pages:
8
EKF’s strong H1 results reflect the operational improvements implemented over the last 18 months. Recovery is now firmly established, with revenues +23% and EBITDA more than doubling in the period. After upgrading 6 times in the last 15 months, we prudently make no further changes at this stage. Growth prospects remain attractive, supported by additional product launches in new territories. We see further mileage as the group remains materially undervalued vs its closest peers and the investment ....